NEW YORK, Aug. 31, 2016 /PRNewswire/ -- Pomerantz LLP is
investigating claims on behalf of investors of Zosano Pharma
Corporation ("Zosano" or the "Company") (NASDAQ: ZSAN). Such
investors are advised to contact Robert S.
Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext.
9980.
[Click here to join a class action]
The investigation concerns whether Zosano and certain of its
officers and/or directors have violated Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934.
On January 27, 2015, Zosano sold
6.5 million shares of stock at $11.00
per share in its initial public offering (the "IPO"), raising over
$71 million in new capital. On
April 7, 2016, after news of the
alleged failure of the Company's lead osteoporosis drug program to
reach commercial viability, Zosano's stock closed at $2.35, a decline of 78.64% since the IPO.
On April 14, 2016, Zosano's stock
closed at $1.95.
The Pomerantz Firm, with offices in New York, Chicago, Los
Angeles, and Florida, is
acknowledged as one of the premier firms in the areas of corporate,
securities, and antitrust class litigation. Founded by the late
Abraham L. Pomerantz, known as the
dean of the class action bar, the Pomerantz Firm pioneered the
field of securities class actions. Today, more than 80 years later,
the Pomerantz Firm continues in the tradition he established,
fighting for the rights of the victims of securities fraud,
breaches of fiduciary duty, and corporate misconduct. The Firm has
recovered numerous multimillion-dollar damages awards on behalf of
class members. See www.pomerantzlaw.com.
CONTACT:
Robert S.
Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-shareholders-of-zosano-pharma-corporation--zsan-300320892.html
SOURCE Pomerantz LLP